1275P - Safety and clinical activity of subcutaneously (SC) administered anti-PD-1 antibody PF-06801591 in phase I dose-expansion cohorts of locally advanced or metastatic non-small cell lung cancer (NSCLC) and urothelial carcinoma (UC)

B.C Cho,K Penkov,I Bondarenko,M Korozan,A Kurochkin,J Pikiel,Y Kulyaba,H.K Ahn,S Odintsova,J Davda,A Forgie,X Wang,R Li,I.A Jacobs,F Kazazi,J Chou,M.L Johnson

doi:10.1093/annonc/mdz253.100

1275P - Safety and clinical activity of subcutaneously (SC) administered anti-PD-1 antibody PF-06801591 in phase I dose-expansion cohorts of locally advanced or metastatic non-small cell lung cancer (NSCLC) and urothelial carcinoma (UC)

B.C Cho, K Penkov + Show 15 more

Open Access

https://doi.org/10.1093/annonc/mdz253.100

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Oct 1, 2019
Citations: 1	License type: publisher-specific-oa

Affiliation: Gachon University Gil Medical Center, Sarah Cannon

#Research Grant #Non-small Cell Lung Cancer Pts + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

1275P - Safety and clinical activity of subcutaneously (SC) administered anti-PD-1 antibody PF-06801591 in phase I dose-expansion cohorts of locally advanced or metastatic non-small cell lung cancer (NSCLC) and urothelial carcinoma (UC)

Full Text